Phaseline

Targets › ALDH1A1

ALDH1A1 (Aldehyde dehydrogenase 1A1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2027.

Cytosolic dehydrogenase that catalyzes the NAD(+)-dependent irreversible oxidation of a wide range of aldehydes to their corresponding carboxylic acid. Functions downstream of retinol dehydrogenases and catalyzes the oxidation of retinaldehyde into retinoic acid, the second step in the oxidation of retinol/vitamin A into retinoic acid. (UniProt, P00352)

Open in Phaseline: the race on ALDH1A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nantes University HospitalPost-Transplant Cyclophosphamide
High-dose cyclophosphamide administered post-transplant for GVHD prophylaxis
ALDH1A1Phase 2Graft Versus Host DiseaseOct 2027

Conditions

Graft Versus Host Disease (1)

Modalities

small molecule (1)

Companies

Nantes University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.